PROM1 and cancer: In conclusion, findings of this study have provided evidence that CD133 is important in the viability of cancer cells and suggest that CD133 downregulation by antisense, alone and in combination with cisplatin, is potentially a new and powerful therapeutic strategy for CD133+ cancers.